8-K 1 tm216076d1_8k.htm FORM 8-K




Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): February 9, 2021


Outlook Therapeutics, Inc.
(Exact name of registrant as specified in its charter)


Delaware   001-37759   38-3982704
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer Identification No.)


4260 U.S. Route 1
Monmouth Junction, New Jersey
(Address of principal executive offices)   (Zip Code)


Registrant's telephone number, including area code: (609) 619-3990



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities pursuant to Section 12 (b) of the Act:


Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which
Common Stock   OTLK   The Nasdaq Stock Market LLC
Series A Warrants   OTLKW   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 3.02 Unregistered Sales of Equity Securities


GMS Private Placement


On February 9, 2021, Outlook Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement with GMS Ventures and Investments (“GMS Ventures”), a significant stockholder of the Company (the “Agreement”), pursuant to which the Company agreed to sell and issue 1,013,627 shares of Common Stock (the “GMS Shares”) at a purchase price of $1.00 per share, for aggregate gross proceeds to the Company of $1,013,627 (the “GMS Private Placement”).


The underwriter in the recently completed underwritten common stock offering partially exercised its overallotment option to purchase additional shares and the GMS Shares were issued to GMS Ventures pursuant to its preemptive rights set forth in Article IV of the Investor Rights Agreement, dated as of September 11, 2017, by and among the Company, BioLexis Pte. Ltd. (“BioLexis”) and GMS Ventures (as amended from time to time, the “BioLexis IRA”). The price per share is the same as that paid by investors in the recently completed underwritten common stock offering and concurrent private placement.


The GMS Shares have not been registered under the Securities Act of 1933, as amended, and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The GMS Private Placement closed on February 10, 2021.


The foregoing description of the GMS Purchase Agreement is not complete and the description is qualified in its entirety by reference to the full text of the GMS Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits.


10.1   Securities Purchase Agreement, dated February 9, 2021, by and between the Company and GMS Ventures and Investments.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Outlook Therapeutics, Inc.
Date: February 11, 2021 By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Chief Executive Officer and Chief Financial Officer